INVESTIGATION

Analysis of filaggrin 2 gene polymorphisms in patients with atopic dermatitis☆,☆☆

Amanda Hertz a,*, Luna Azulay-Abulafia b, Adriana Paulino do Nascimento c, Cintya Yumi Ohara d, Fabio Chigres Kuschnir e,f, Luís Cristovão Porto e,c

a Pediatric Dermatology Clinic, Instituto de Dermatologia Prof. Rubem David Azulay, Rio de Janeiro, RJ, Brazil
b Department of Dermatology, Instituto de Dermatologia Prof. Rubem David Azulay, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
c Histocompatibility and Cryopreservation Laboratory, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
d Department of Allergy and Immunopathology, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
e Department of Pediatrics, Faculdade de Ciências Médicas, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
f Department of Allergy, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil

Received 8 July 2018; accepted 26 July 2019
Available online 25 January 2020

KEYWORDS
Allergy;
Dermatitis, atopic;
Immunology;
Polymorphism, genetic

Abstract
Background: Polymorphisms of the filaggrin 2 gene (rs 12568784 and rs 16899374) are associated with persistent atopic dermatitis in African American patients. Filaggrin 2 is a protein with a function similar to filaggrin and also encoded in the epidermal differentiation complex on chromosome 1q21.
Objective: To evaluate the polymorphisms in the filaggrin 2 gene (rs 12568784 and rs 16899374) in children and adults with atopic dermatitis and to verify the association of these with the severity of the clinical picture, presence of other allergic diseases, and socio-demographic factors.
Method: The study was carried out with patients and control group. Questionnaires were used to evaluate ethnicity, sex, age, family history, scoring, atopic dermatitis (SCORAD), among other parameters. Genotyping of the filaggrin 2 gene was performed by real-time polymerase chain reaction.
Results: Forty-eight patients and 83 controls were evaluated. No correlation was found between the variables studied in patients with atopic dermatitis and polymorphisms, no significant difference between the prevalence of polymorphisms in the patients and in the control group $p > 0.05$.

☆ How to cite this article: Hertz A, Azulay-Abulafia L, Nascimento AP, Ohara CY, Kuschnir FC, Porto LC. Analysis of filaggrin 2 gene polymorphisms in patients with atopic dermatitis. An Bras Dermatol. 2020;95:173–9.
☆☆ Study conducted at the Atopic Dermatitis Clinic, Oliclínica Piquet Carneiro, Universidade do Estado do Rio de Janeiro, RJ, Brazil.
* Corresponding author.
E-mail: hertzamanda@gmail.com (A. Hertz).

https://doi.org/10.1016/j.abd.2019.07.002
0365-0596/© 2020 Sociedade Brasileira de Dermatologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Introduction

Atopic dermatitis (AD) is a frequent inflammatory skin disease that affects approximately 20% of children, compromising the quality of life of the patient and the family. Mutations in the gene encoding the filaggrin epidermal protein have been shown to be an important factor in the development of this disease. Filaggrin is also associated with the persistence and coexistence of other allergic diseases.

The filaggrin (FILAGGRIN: FI lament AGGRegating proteIN) is a protein found in cornocytes responsible for aggregating keratin in the formation of stratum corneum. It is produced from a precursor, pro-filaggrin, which is located in the granular layer of the epidermis in the granules of keratohyalin. Pro-filaggrin is subsequently dephosphorylated, resulting in the formation of filaggrin monomers having keratin filament aggregation properties. Filaggrin degradation generates Natural Moisturizing Factors (NMFs), which include free amino acids, Urocanic Acid (UCA), and Carboxylic Pyrrolidonic Acid (PCA). NMFs promote water uptake and entrapment, and maintenance of acidic pH of the skin, essential for the process of hydration and maintenance of the skin barrier.

The gene encoding filaggrin is located on chromosome 1q21, in a region called epidermal differentiation complex. According to the literature, 27.5% of Caucasian Americans, 48% of Europeans, 31.4% of Chinese and 20% of Japanese with AD present mutations in the filaggrin gene.

Currently, 47 mutations with loss of function have already been identified in the gene encoding filaggrin in patients with AD. Profiles other than mutations were identified in patients from Europe and Asia. Among the mutations described, the most commonly found in Caucasians are R501X and 2282del4 (comprising 50% of the total), in addition to R2447X and S3247X. In the Japanese population, the main mutations were 3321delA and S2554X. These mutations seem to vary according to ethnic groups, for example, in the African-American population studies have shown a much lower prevalence than in Caucasians. Gao et al. found that R501X was found in 3.2% of 187 African-American patients with AD and no association with 2282 of the 4 patients.

Margolis et al. evaluated the genotype of 370 African Americans with AD and found mutations in only 1% of patients (R501X, 3.2%; 2282del4, 0.5%; S3247X, 3% and R2447X, 1.4%).

Filaggrin 2 is a protein whose function is similar to filaggrin and also encoded in the region called epidermal differentiation complex, according to Makino et al. the expression of filaggrin 2 protein is decreased in patients with AD. There is an association between polymorphisms in the filaggrin 2 gene (rs 12568784 and rs 168937411) and persistent AD in African American patients with atopic dermatitis.

The aim of this study was to evaluate the polymorphisms in the filaggrin 2 gene (rs 12568784 and rs 16893741) in children and adults with atopic dermatitis and to verify the association of these with the severity of the clinical picture, presence of other allergic diseases and socio-demographic factors.

Methods

A cross-sectional study involving patients of both sexes, aged between 1 and 27 years, diagnosed with atopic dermatitis, according to United Kingdom Working Party (UK) criteria, recruited from outpatient clinics for atopic dermatitis. Patients with other chronic diseases of the skin (psoriasis, among others) or systemic diseases that affect the skin, such as primary immunodeficiencies, systemic lupus erythematosus were excluded.

According to the order of arrival in the clinic, the patients answered a questionnaire with the following variables: gender, age, ethnicity, onset of AD, family history of allergic diseases and presence of asthma, food allergy and rhinitis. The ISAAC questionnaire, validated for our language, was used to evaluate the presence of asthma and rhinitis. In addition, the severity of AD was analyzed by SCORAD (Scoring Atopic Dermatitis). The severity levels of AD were defined as light: SCORAD up to 25 points; moderate between 25–50 points; and serious, above 50 points.

After signing of consent terms, venous blood samples were collected in tubes containing EDTA. In order to increase the reliability of the study and because of the ethical difficulty of creating a pediatric control group with blood collection, control samples from the same population group from a bone marrow bank were chosen, which were matched by sex and ethnicity.

To determine the genetic variation of filaggrin 2, the genomic DNA of the individuals participating in the study was purified using the QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA) according to the manufacturer’s instructions. The principle of this kit is based on the extraction of genomic DNA from nucleated blood cells and subsequent binding of the DNA to a glass fiber matrix contained in a MicroSpin column. Briefly, after digestion of the cell membranes by proteinase K, the nucleic material was transferred to a silica membrane where it was subjected to several washes with alcoholic solutions. The elution was done by the addition of ultrapure water. The genomic DNA was quantified by measuring the absorbance at the optical density of 260 nm.
(OD260) using the NanoDrop Lite spectrophotometer (ThermoScientific). The final preparation was stored at −20 °C.

Genotyping of the filaggrin 2 gene (rs16833974 and rs12568784) was performed by real-time PCR using commercially available Taqman® (ABI assay; AppliedBiosystems) probe labeled with the VIC and FAM fluorophores for each allele, C32456909.10 for rs16833974 and C11261511 to rs12568784. Briefly, the reaction was performed in a final volume of 10 µL containing 40 ng of genomic DNA, Taqman SNP Genotyping Assays 40X and TaqmanGenotyping Master Mix according to the manufacturer’s instructions. Initially the samples were subjected to a pre-PCR reading step at 60 °C for 30 s, followed by the denaturation step at 95 °C for 10 min. Then the amplification stage consisted of 40 cycles of 95 °C for 15 s and 60 °C for 1 min, for annealing of the primer and extension of the fragments. After amplification of the DNA fragments, the samples were submitted to the final post-PCR reading step at 60 °C for 30 s. The PCR reaction was performed with the aid of the ABI StepOnePlus Real-Time PCR System (AppliedBiosystems, Foster City, CA). The results of the allelic discrimination analysis were plotted on a scatter plot contrasting the fluorescence of each probe. In order to increase the reliability of the study in relation to mutation analysis, control samples from a bone marrow bank were analyzed.

Statistical analysis

A sample of 48 patients with a larger control group (1.7 times) of 83 patients was used for a better statistical analysis. The frequency and relative frequency statistics were used to present the variables in descriptive tables, in order to understand the profile of the sample and also of the controls. In order to verify possible associations, the Chi-square test, or Fisher’s exact test, was used to identify evidence that shows the significance of certain variables in relation to the genetic mutation studied and SCORAD (Scoring atopic dermatitis) level.

The significance level of 0.05, p-value <0.05 was used to evaluate the associations between the dependent variable (mutations in the filaggrin 2 gene) and the other variables of interest in the study. The programs Microsoft Excel 2010 and Software R, version 3.3.1 (R Core Team 2015, Vienna, Austria) were employed for organizing, creating tables and statistical analysis of data. The study followed the principles of the Helsinki Declaration and was approved by the ethics committee under opinion n 36934514.9.0000.5259.

Results

From November 2015 to February 2016 data were collected from 48 patients, 54% male. The control group consisted of 83 samples. The total polymorphism prevalence rs16833974 in the group of patients was 16.7% (14.6% heterozygote and 2.1% homozygous) and 15.7% in the control group (15.7% heterozygous) and the total prevalence of rs polymorphism rs12568784 were: 43.7% of the patients (35.4% heterozygous and 8.3% homozygous) and control: 46.9% (37.3% heterozygous and 9.6% homozygous). The main characteristics of the sample and the control group are described in table 1.

The genetic polymorphism distribution of rs 16833974 and rs 12568784 according to the socio demographic variables of the sample and the control group are respectively shown in table 2.

The main variables studied were: gender, ethnicity, SCORAD, family history of atopy and associated allergic diseases. As for polymorphism rs 16833974, statistically significant differences were found regarding the ethnicity variable, and the darker the skin color the greater the chance of having the polymorphism, p-value = 0.031 (Table 3).

As for polymorphism rs12568784, the following variables were also studied: sex, ethnicity, SCORAD, family history of atopy and associated allergic diseases (food allergy, asthma and rhinitis) and no statistical significance was found among the variables except for the parent variable. The test had p-value = 0.032, which was lower than the significance level of 0.05 (5%). Given this, it is possible to affirm the existence of statistical evidences that prove some causal relation between polymorphism and Atopy (Father). According to the data in the table we can see a reduction in polymorphism rs12568784 in the presence of Atopia (Pai) (Table 4).

A total of 46 crosses of interest were performed in order to verify statistical significance between polymorphism and family history, sex, ethnicity, disease severity, atopy (asthma, rhinitis, familial allergy) and comparison with control of mutation frequency, ethnicity and sex. We sought to perform evaluation separately from heterozygous and homozygous polymorphisms, but no association was found.

Discussion

The relationship between polymorphisms of the filaggrin 2 gene and AD has recently been reported. According to the literature, filaggrin 2 polymorphism may influence the severity of the disease. In this study, we sought to analyze some points of this association in a broad way, through the exploratory analysis and correlation of clinical and demographic data.

It is important to consider that the control group used in the study was of convenience, with samples of bone marrow bank, due to the difficulty of organizing a control group of children. A gender and ethnicity pairing was performed between the groups. This is the first work that uses controls to evaluate polymorphisms of filaggrin 2 and DA. No statistical differences were found between the prevalence of polymorphisms in the group of patients with AD and in the control group. In addition, there was no difference in severity in patients with polymorphism.

Likewise, when we analyzed the correlations between age at onset of AD and polymorphisms, there were no statistical differences. As described by Margolis et al., no association of polymorphism with other atopic-valued diseases (asthma, rhinitis, food allergy) was also found.

Family history is an important risk factor for the development of AD. Approximately 70% of patients with AD present a family history of atopic diseases. The probability of developing AD is about two to three times greater in children with one atopic parent, and increases to three to five times if both parents are atopic. In general, the maternal his-
In our study, 85% of the patients presented positive family history for atopy, corroborating the literature.

In general, no statistical differences were observed between family history of atopy and filaggrin polymorphisms 2, except for the frequency of the polymorphism mutation rs 12568784 in the presence of paternal atopy. This data can only refer to a statistical finding, due to

**Table 1** Distribution of socio-demographic data of patients and controls

| Sociodemographics variables | Patients | | Control | |
|-----------------------------|----------|--------|---------|--------|
|                             | n        | %      | n       | %      |
| Sex                         |          |        |         |        |
| F                           | 22       | 46%    | 33      | 40%    | 0.58   |
| M                           | 26       | 54%    | 50      | 60%    |        |
| Ethnicity                   |          |        |         |        |
| White                       | 17       | 35%    | 29      | 35%    |        |
| Brown                       | 12       | 25%    | 26      | 31%    | 0.51   |
| African american            | 18       | 38%    | 28      | 34%    |        |
| Unidentified                | 1        | 2%     | 0       | 0%     |        |
| Age                         |          |        |         |        |
| Infant (0–2 years)          | 4        | 8%     | 21–30 years | 55 | 66% |
| Children (3–9 years)        | 28       | 58%    | 31–45 years | 21  | 25% |
| Adolescent (10–19 years)    | 13       | 27%    | >45 years | 6    | 7%  |
| Adult (20 years or more)    | 3        | 6%     | Unidentified | 1  | 1%  |

**Table 2** Distribution of the rs16833974 and rs12568784 polymorphism according to the sociodemographic variables of the patients and control group

| Sociodemographics variables | Polymorphism rs16833974 | Polymorphism rs12568784 |
|-----------------------------|--------------------------|-------------------------|
|                             | Patients                 | Control                 | Patients | Control | |
|                             | Present | Absent | p-Value | Present | Absent | p-Value | Present | Absent | p-Value | |
|                             | n       | %      |         | n       | %      |         | n       | %      |         | n       | %      |         |
| Sex                         |          |        |         |         |        |         |         |        |         |         |        |         |         |
| F                           | 4       | 8%     | 18      | 38%     | 1      | 5       | 6%     | 28      | 34%     | 0.14    |         |         |         |
| M                           | 4       | 8%     | 22      | 46%     | 8      | 10%    | 42      | 51%     |         |         |         |         |         |         |
| Ethnicity                   |          |        |         |         |        |         |         |        |         |         |         |         |         |         |
| White                       | 1       | 2%     | 16      | 33%     | 0.08   | 1       | 1%     | 28      | 34%     | 0.03    |         |         |         |         |
| Brown                       | 1       | 2%     | 11      | 23%     | 4      | 5%     | 22      | 27%     |         |         |         |         |         |         |
| African American            | 6       | 13%    | 12      | 25%     | 8      | 10%    | 20      | 24%     |         |         |         |         |         |         |
| Unidentified                | 0       | 0%     | 1       | 2%      | 0      | 0%     | 0       | 0%      |         |         |         |         |         |         |
| Sociodemographics variables |          |        |         |         |        |         |         |        |         |         |         |         |         |         |
|                             |          |        |         |         |        |         |         |        |         |         |         |         |         |         |
| Sex                         |          |        |         |         |        |         |         |        |         |         |         |         |         |         |
| F                           | 11      | 23%    | 11      | 23%     | 0.56   | 19      | 23%    | 14      | 17%     | 0.17    |         |         |         |         |
| M                           | 10      | 21%    | 16      | 33%     |         | 20      | 24%    | 30      | 36%     |         |         |         |         |         |         |
| Ethnicity                   |          |        |         |         |        |         |         |        |         |         |         |         |         |         |
| White                       | 7       | 15%    | 10      | 21%     | 0.38   | 10      | 12%    | 19      | 23%     | 0.51    |         |         |         |         |
| Brown                       | 3       | 6%     | 9       | 19%     |         | 17      | 20%    | 9       | 11%     |         |         |         |         |         |         |
| African American            | 10      | 21%    | 8       | 17%     |         | 12      | 14%    | 16      | 19%     |         |         |         |         |         |         |
| Unidentified                | 1       | 2%     | 0       | 0%      |         | 0       | 0%     | 0       | 0%      |         |         |         |         |         |         |
Table 3. Variables studied in the patient’s group and polymorphism rs16833974

| Variables   | Polymorphism rs 16833974 | Total | p-Value |
|-------------|--------------------------|-------|---------|
|             | Present | Absent | n   | %   | n   | %   |
| Sex         | F       | 4      | 50% | 18  | 45% | 22  | 46% | 1   |
|             | M       | 4      | 50% | 22  | 55% | 26  | 54% |     |
| Scorad      |         |        |     |     |     |     |     |     |
| Mild        | 6       | 75%    | 13  | 33% | 19  | 40% | 0.026 |
| Moderate    | 2       | 25%    | 15  | 38% | 17  | 35% |     |
| Severe      | 0       | 0%     | 10  | 25% | 10  | 21% |     |
| Unidentified| 0       | 0%     | 2   | 5%  | 2   | 4%  |     |
| Total       | 8       | 100%   | 40  | 100%| 48  | 100%|     |
| HF Atopia   |         |        |     |     |     |     |     | 0.56 |
| Yes         | 8       | 100%   | 33  | 83% | 41  | 85% |     |
| No          | 0       | 0%     | 5   | 13% | 5   | 10% |     |
| Unidentified| 0       | 0%     | 2   | 5%  | 2   | 4%  |     |
| Total       | 8       | 100%   | 40  | 100%| 48  | 100%|     |
| Mother      |         |        |     |     |     |     |     | 0.7  |
| Yes         | 5       | 63%    | 18  | 45% | 23  | 48% |     |
| No          | 3       | 38%    | 17  | 43% | 20  | 42% |     |
| Unidentified| 0       | 0%     | 5   | 13% | 5   | 10% |     |
| Total       | 8       | 100%   | 40  | 100%| 48  | 100%|     |
| Father      |         |        |     |     |     |     |     | 0.24 |
| Yes         | 6       | 75%    | 16  | 40% | 22  | 46% |     |
| No          | 2       | 25%    | 19  | 48% | 21  | 44% |     |
| Unidentified| 0       | 0%     | 5   | 13% | 5   | 10% |     |
| Total       | 8       | 100%   | 40  | 100%| 48  | 100%|     |
| Ethnicity   |         |        |     |     |     |     |     | 0.031 |
| White       | 1       | 13%    | 16  | 40% | 17  | 35% |     |
| Brown       | 1       | 13%    | 11  | 28% | 12  | 25% |     |
| African American | 6 | 75% | 12 | 30% | 18 | 38% |     |
| Unidentified| 0       | 0%     | 1   | 3%  | 1   | 2%  |     |
| Total       | 8       | 100%   | 40  | 100%| 48  | 100%|     |
| Asthma      |         |        |     |     |     |     |     | 0.66 |
| Yes         | 4       | 50%    | 18  | 45% | 22  | 46% |     |
| No          | 2       | 25%    | 19  | 48% | 21  | 44% |     |
| Unidentified| 2       | 25%    | 3   | 8%  | 5   | 10% |     |
| Total       | 8       | 100%   | 40  | 100%| 48  | 100%|     |
| Food allergy|         |        |     |     |     |     |     | 0.37 |
| Yes         | 1       | 13%    | 15  | 38% | 16  | 33% |     |
| No          | 5       | 63%    | 22  | 55% | 27  | 56% |     |

the small sample number and possibly without biological plausibility. More studies are needed to elucidate this finding.

According to Margolis et al. (2014), filaggrin gene polymorphisms 2, rs 12568784 and rs 16833974, are associated with the persistence of AD in African Americans and are absent or are rarely found in individuals of European origin. In the study population, there was statistical significance among the patients with autodeclared black AD and the polymorphisms rs 16833974.

The Brazilian population has a high degree of miscegenation and follows different ethnic patterns when compared to population groups from other countries and continents such as China, the United States, Japan and Europe, where there are already studies with the prevalence of filaggrin. Therefore, it is difficult to establish a classification by ethnicities in our country. The exclusive use of information of the self-declared ethnic group is not the best method for ethnic classification.
**Table 4** Variables studied in the patient's group and polymorphism rs1256878

| Variables                          | Polymorphism rs12568784 | Total | $p$-Value |
|-----------------------------------|-------------------------|-------|-----------|
|                                   | Present | Absent | n | % | n | % |          |
| **Sex**                           |         |         |   |   |   |   |          |
| F                                 | 11      | 11      | 22 | 46% | 0.56 |
| M                                 | 10      | 16      | 26 | 54% |       |
| Total                             | 21      | 27      | 48 | 100%|       |
| **Scorad**                        |         |         |   |   |   |   |          |
| Mild                              | 9       | 10      | 19 | 40% | 0.91 |
| Moderate                          | 5       | 12      | 17 | 35% |       |
| Severe                            | 5       | 5       | 10 | 21% |       |
| Unidentified                      | 2       | 0       | 2  | 4%  |       |
| Total                             | 21      | 27      | 48 | 100%|       |
| **Family history atopia**         |         |         |   |   |   |   |          |
| Yes                               | 20      | 21      | 41 | 85% | 0.059|
| No                                | 0       | 5       | 5  | 10% |       |
| Unidentified                      | 1       | 4       | 2  | 4%  |       |
| Total                             | 21      | 27      | 48 | 100%|       |
| **Mother**                        |         |         |   |   |   |   |          |
| Yes                               | 11      | 12      | 23 | 48% | 1     |
| No                                | 9       | 11      | 20 | 42% |       |
| Unidentified                      | 1       | 4       | 5  | 10% |       |
| Total                             | 21      | 27      | 48 | 100%|       |
| **Father**                        |         |         |   |   |   |   |          |
| Yes                               | 14      | 8       | 22 | 46% | 0.032|
| No                                | 6       | 15      | 21 | 44% |       |
| Unidentified                      | 1       | 4       | 5  | 10% |       |
| Total                             | 21      | 27      | 48 | 100%|       |
| **Ethnicity**                     |         |         |   |   |   |   |          |
| White                             | 7       | 10      | 17 | 35% | 0.38 |
| Brown                             | 3       | 9       | 12 | 25% |       |
| African American                  | 10      | 8       | 18 | 38% |       |
| Unidentified                      | 1       | 0       | 1  | 2%  |       |
| Total                             | 21      | 27      | 48 | 100%|       |
| **Asthma**                        |         |         |   |   |   |   |          |
| Yes                               | 8       | 14      | 22 | 46% | 0.54 |
| No                                | 10      | 11      | 21 | 44% |       |
| Unidentified                      | 3       | 2       | 5  | 10% |       |
| Total                             | 21      | 27      | 48 | 100%|       |
| **Food allergy**                  |         |         |   |   |   |   |          |
| Yes                               | 6       | 10      | 16 | 33% | 0.75 |
| No                                | 12      | 15      | 27 | 56% |       |
| Unidentified                      | 3       | 2       | 5  | 10% |       |
| Total                             | 21      | 27      | 48 | 100%|       |

The genomes of most Brazilians are miscegenated and genetic markers are capable of providing valuable new insights into the current structure of the Brazilian population.\(^9\)

Future prospects of ancestral analysis of blood samples from our study may allow a better understanding of the association between filaggrin 2 and DA, since the prevalence of filaggrin gene mutations show ethnic differences in both the general population and individuals with DA.\(^10\)

The small sample size may have limited the significance of our results and perhaps a larger sample and/or ancestral study may contribute to the clarification between individuals with AD and filaggrin polymorphisms 2. The performance of the proteical study of filagrin 2, since structural differ-
ences may be due to post-transcriptional controls, would also contribute to a better evaluation of filaggrin 2.

To date, there are no studies of filaggrin 2 and DA gene polymorphisms in Latin America, reinforcing the relevance of our study and the novelty of this initiative in Brazil. In addition, this is the first worldwide study using a control group to evaluate changes in the filaggrin gene 2.

Conclusion

Very little is known about the profile of filaggrins 2 polymorphisms associated with AD in the highly mixed Brazilian population. The results of this work can be a considerable incentive to research on polymorphisms and AD in the country, collaborating to a better understanding, not only of ways of treating the disease, but also of the genetic profile of the population.

As for polymorphism rs 16833974, statistically significant differences were found regarding the ethnicity variable, and the darker the skin color the greater the chance of having the polymorphism, p-value = 0.031.

Financial support

This work was carried out with the financial support of Fundo de Apoio à Dermatologia (FUNADERM) of the Brazilian Society of Dermatology.

Authors’ contributions

Amanda Hertz: Conception and planning of the study; obtaining, analysis, and interpretation of the data; critical review of the literature.

Luna Azulay-Abulafia: Effective participation in research orientation.

Adriana Paulino do Nascimento: Conception and planning of the study; obtaining, analysis, and interpretation of the data.

Cintya Yumi Ohara: Conception and planning of the study. Fabio Chigres Kuchnir: Critical review of the literature; critical review of the manuscript.

Luis Cristovão Porto: Conception and planning of the study; obtaining, analysis, and interpretation of the data.

Conflicts of interest

None declared.

References

1. Baurecht H, Irvine AD, Novak N, Illig T, Bühler B, Ring J, et al. Toward a major risk factor for atopic eczema: meta-analysis of filaggrin polymorphism data. J Allergy Clin Immunol. 2007;120:1406–12.

2. Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med. 2011;365:1315.

3. Sandilands A, Sutherland C, Irvine AD, McLean WH. Filaggrin in the frontline: role in skin barrier function and disease. J Cell Sci. 2009;122:1285–94.

4. Mócsai G, Gáspár K, Nagy G, Irinyi B, Kapitány A, Bíró T, et al. Severe skin inflammation and filaggrin mutation similarly alter the skin barrier in patients with atopic dermatitis. Br J Dermatol. 2014;170:617–24.

5. Polcari I, Becker L, Stein SL, Smith MS, Pallier AS. Filaggrin gene mutations in African Americans with both ichthyosis vulgaris and atopic dermatitis. Pediatr Dermatol. 2014;31:489–92.

6. Flohr C, England K, Rudolovic S, McLean WH, Campbel LE, Barker J, et al. Filaggrin loss-of-function mutations are associated with early-onset eczema, eczema severity and transepidermal water loss at 3 months of age. Br J Dermatol. 2010;163:1333–6.

7. Margolis DJ, Apter AJ, Gupta J, Hoffstad O, Papadopoulos M, Campbell LE, et al. The persistence of atopic dermatitis and filaggrin (FLG) mutations in a US longitudinal cohort. J Allergy Clin Immunol. 2012;130:912–7.

8. Vercelli DMD. Advances in asthma and allergy genetics in 2007. J Allergy Clin Immunol. 2008;122:267–71.

9. Bieber T. Atopic dermatitis. N Engl J Med. 2008;358:1483–94.

10. Gao PS, Rafaeis NW, Hand T, Murray T, Boguniewicz M, Hata T, et al. Filaggrin mutations that confer risk of atopic dermatitis confer greater risk for eczema herpeticum. J Allergy Clin Immunol. 2009;124:507–13.

11. Makino T, Mizawa Y, Yamakoshi T, Takaishi M, Shimizu T. Expression of filaggrin-2 protein in the epidermis of human skin diseases: a comparative analysis with filaggrin. Biochem Biophys Res Commun. 2014;449:100–6.

12. Margolis DJ, Gupta J, Apter AJ, Ganguly T, Hoffstad O, Papadopoulos M, et al. Filaggrin-2 variation is associated with more persistent atopic dermatitis in African American subjects. J Allergy Clin Immunol. 2014;133:784–9.

13. Williams HC, Burney PG, Hay RJ, Archer CB, Shipley MJ, Hunter JJ, et al. The U.K. Working Party’s Diagnostic Criteria for Atopic Dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol. 1994;131:383–96.

14. Solé D, Vanna AT, Yamada E, Rizzo MC, Naspitz CK. International Study of Asthma and Allergies in Childhood (ISAAC) written questionnaire: validation of the asthma component among Brazilian children. J Investig Allergol Clin Immunol. 1998;8:376–82.

15. Vanna AT, Yamada E, Arruda LK, Naspitz CK, Solé D. International study of asthma and allergies in childhood: validation of the rhinitis symptom questionnaire and prevalence of rhinitis schoolchild in São Paulo Brazil. Pediatr Allergy Immunol. 2001;12:95–101.

16. Oranje AP, Glazenburg EJ, Wolkerstorfer A, de Waard van der Spek FB. Practical issues on interpretation of scoring atopic dermatitis: the SCORAD index, objective SCORAD and the three-item severity score. Br J Dermatol. 2007;157:645–8.

17. Wadonda Kabondo N, Sterne JA, Golding J, Kennedy CT, Archer CB, Dunnill MG, ALSPEC Study Team. Association of parental eczema, hay fever, and asthma with atopic dermatitis in infancy: birth cohort study. Arch Dis Child. 2004;89:917–21.

18. Ruiz RG, Kemeny DM, Price JF. Higher risk of infantile atopic dermatitis from maternal atopy than from paternal atopy. Clin Exp Allergy. 1992;22:762–6.

19. Cardena MMS, Santos AR, Santos S, Mansur AJ, Pereira AC, Fridman C. Relação entre a etnia auto-declarada, haplogrupo mitocondrial e ancestralidade genômica em indivíduos do sudoeste brasileiro. Saúde Etica Justiça. 2013;18:62–6.

20. Winge MCG, Bradley M. Prevalence of filaggrin gene mutations: an evolutionary perspective. In: Thyssen JP, Maibach HI, editors. Filaggrin, vol. 1. 2014. p. 119–28.